Lido Advisors’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
Other funds holding RLMD
JHC
Lido Advisors's RLMD Position: Q3 2026 in Review
Lido Advisors reduced its Relmada Therapeutics (RLMD) stake by 0.56% in Q3 2026, selling an estimated $383 and leaving 13,827 shares worth $52.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2013.
Lido Advisors first reported a position in RLMD in Q1 2025 and has held it in 7 quarters since. The position peaked at $96.8K in Q1 2026. 135 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.
- Lido Advisors held 13,827 shares of Relmada Therapeutics worth $52.1K as of Q3 2026.
- Lido Advisors sold 78 Relmada Therapeutics shares in Q3 2026, an estimated $383.
- Relmada Therapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q3 2026, its #2013 holding.
- Lido Advisors first reported a position in Relmada Therapeutics in Q1 2025 and has held it in 7 quarters since.
- Lido Advisors's Relmada Therapeutics position peaked at $96.8K in Q1 2026.
- 135 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.
Based on Lido Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.